Self-Irradiation Effects on 99Mo Reagents and Products
S. D. Carson, M. J. McDonald, D. R. Tallant, M. J. Garcia, R. L. Simpson
In September 1996, the U.S. Department of Energy (DOE) signed a Record of Decision authorizing Sandia National Laboratories in Albuquerque to establish a production capability for Mo-99, the precursor of the medical isotope Tc-99m, and related medical isotopes at its reactor and hot-cell facilities. Using the existing facilities, pilot batches of Mo-99 that passed industry purity specifications were produced in 1996 and shipped to pharmaceutical houses for evaluation of compatibility with their processes. Once this milestone was achieved, facilities modifications and the Food and Drug Administration validation process for full-scale production were begun. As part of the process validation, possible negative effects of the high radiation field produced by Mo-99 on both processing reagents and product were considered.
This abstract was presented at the 32nd Annual Midyear Meeting, "Creation and Future Legacy of Stockpile Stewardship Isotope Production, Applications, and Consumption", Isotope Production, Applications, and Safety Session, 1/24/1999 - 1/27/1999, held in Albuquerque, NM.